Wall Street analyst estimates for None (GDTC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $365604 | $509125 | $69501 | $319201 |
| Cost of Revenue | 0 | $4627 | $3501 | $109042 | $3736 | $17121 | $1.2M |
| Gross Profit | 0 | $54836 | $110291 | -$109042 | $505387 | $52380 | -$886564 |
| Research & Development | $439796 | $1.0M | $1.1M | $1.5M | $1.6M | $1.9M | $2.2M |
| Selling, General & Admin | $40346 | $154862 | $588459 | $596506 | $490491 | $1.3M | $1.4M |
| Operating Expenses | $651880 | $1.2M | $1.3M | $2.2M | $2.1M | $3.2M | $3.6M |
| Operating Income | -$651880 | -$1.3M | -$1.2M | -$2.3M | -$1.6M | -$3.1M | -$4.5M |
| EBITDA | -$474603 | -$1.0M | -$1.4M | -$1.5M | -$3.9M | -$2.0M | -$4.3M |
| Interest Expense | 0 | $105512 | $118392 | $122147 | $50522 | $20313 | $20571 |
| Pre-tax Income | -$858748 | -$1.9M | -$2.1M | -$3.1M | -$4.1M | -$2.6M | -$3.9M |
| Income Tax | 0 | 0 | 0 | $1599 | $653 | -$54725 | 0 |
| Net Income | -$858748 | -$1.9M | -$2.1M | -$3.1M | -$4.1M | -$2.5M | -$3.9M |
| EPS | $-0.15 | $-0.33 | $-0.30 | $-0.40 | $-0.38 | $-0.22 | $-0.33 |
| EPS (Diluted) | $-0.15 | $-0.33 | $-0.30 | $-0.40 | $-0.38 | $-0.22 | $-0.33 |
| Shares Outstanding (Diluted) | $5.6M | $5.9M | $6.9M | $7.9M | $10.6M | $11.5M | $11.6M |
Related companies: CLGN · ENLV · LSTA · MTVA · NCNA · NRSN · NRXS
More sections of GDTC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks